Format

Send to

Choose Destination
Cancer Lett. 2014 Oct 10;353(1):1-7. doi: 10.1016/j.canlet.2014.07.014. Epub 2014 Jul 29.

Nitric oxide in cancer metastasis.

Author information

1
Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701, USA; Edison Biotechnology Institute, Konneker Research Center, Ohio University, Athens, OH 45701, USA.
2
School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
3
Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701, USA; Edison Biotechnology Institute, Konneker Research Center, Ohio University, Athens, OH 45701, USA. Electronic address: wus1@ohio.edu.
4
School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH 43210, USA. Electronic address: zuo.4@osu.edu.

Abstract

Cancer metastasis is the spread and growth of tumor cells from the original neoplasm to further organs. This review analyzes the role of nitric oxide (NO), a signaling molecule, in the regulation of cancer formation, progression, and metastasis. The action of NO on cancer relies on multiple factors including cell type, metastasis stage, and organs involved. Various chemotherapy drugs cause cells to release NO, which in turn induces cytotoxic death of breast, liver, and skin tumors. However, NO has also been clinically connected to a poor cancer prognosis because of its role in angiogenesis and intravasation. This supports the claim that NO can be characterized as both pro-metastatic and anti-metastatic, depending on specific factors. The inhibition of cell proliferation and anti-apoptosis pathways by NO donors has been proposed as a novel therapy to various cancers. Studies suggest that NO-releasing non-steroidal anti-inflammatory drugs act on cancer cells in several ways that may make them ideal for cancer therapy. This review summarizes the biological significance of NO in each step of cancer metastasis, its controversial effects for cancer progression, and its therapeutic potential.

KEYWORDS:

Hypoxia; NSAIDs; Signaling; Tumor; iNOS

PMID:
25079686
PMCID:
PMC4150837
DOI:
10.1016/j.canlet.2014.07.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center